Beyond Air, Inc. (XAIR) CEO buys stock plus FDA-linked Series A and B warrants

Rhea-AI Filing Summary

Beyond Air, Inc. Chief Executive Officer Robert Scott Goodman purchased 34,722 shares of common stock on July 29, 2026 at $5.76 per share, bringing his direct common stock holdings to 34,822 shares. He also acquired 34,722 Series A Warrants and 34,722 Series B Warrants, each exercisable for common stock at $5.51 per share. The warrants are exercisable immediately; the Series A Warrants expire on the earlier of one year after issuance or 45 days following FDA approval of the company’s pending premarket approval supplement for LungFit PH II, while the Series B Warrants expire five years after issuance.

Insider Trade Summary

Net Buyer: 34,722 shares

Net Buy 3 txns

Insider Goodman Robert Scott

Role Chief Executive Officer

Bought 104,166 shs

Type	Security	Shares	Price	Value
Purchase	Series A Warrants F3, F1, F2	34,722	--	--
Purchase	Series B Warrants F3, F1, F4	34,722	--	--
Purchase	Common Stock	34,722	$5.76	$200K

Holdings After Transaction: Series A Warrants — 34,722 shares (Direct); Series B Warrants — 34,722 shares (Direct); Common Stock — 34,822 shares (Direct)

Footnotes (4)

1. F1. Exercisable immediately upon issuance
2. F2. Expiration on the earlier of (i) the first anniversary of their issuance or (ii) the date that is 45 days following approval by the FDA of the Company's pending premarket approval supplement for LungFit PH II
3. F3. Each Series A Warrant and Series B Warrant was purchased together with one share of common stock for a combined purchase price of $5.76.
4. F4. 5 years following date of issuance

Key Figures

Common shares purchased: 34,722 shares Common stock purchase price: $5.76 per share Common shares held after transaction: 34,822 shares +5 more

8 metrics

Common shares purchased 34,722 shares Common stock acquired by CEO on July 29, 2026

Common stock purchase price $5.76 per share Price paid for Beyond Air common stock on July 29, 2026

Common shares held after transaction 34,822 shares Direct common stock holdings of CEO following purchase

Series A Warrants acquired 34,722 warrants Series A Warrants exercisable for common stock acquired on July 29, 2026

Series B Warrants acquired 34,722 warrants Series B Warrants exercisable for common stock acquired on July 29, 2026

Warrant exercise price $5.51 per share Conversion or exercise price for both Series A and Series B Warrants

Combined bundle price $5.76 per bundle One share of common stock plus one Series A and one Series B Warrant

Series B Warrant term 5 years Expiration is 5 years following the date of issuance

Key Terms

Series A Warrants, Series B Warrants, premarket approval supplement, LungFit PH II, +1 more

5 terms

Series A Warrants financial

"acquired 34,722 Series A Warrants exercisable for common stock"

Series A warrants are financial tools that give the holder the right to buy shares of a company at a specific price within a certain period. They are often issued alongside investments to provide additional potential profit if the company's value increases. For investors, they can offer a chance to benefit from future growth without committing immediate capital to buying shares.

Series B Warrants financial

"acquired 34,722 Series B Warrants exercisable for common stock"

Series B warrants are contracts issued alongside a company's Series B financing that give the holder the right to buy a set number of shares at a fixed price within a specified time. For investors, they matter because they can provide leveraged upside if the company grows, or they can dilute existing shareholders when exercised—like a coupon promising a future share at a known price that can add value or change ownership stakes.

premarket approval supplement medical

"pending premarket approval supplement for LungFit PH II"

A premarket approval supplement is a regulatory submission seeking permission to change a medical device that already has FDA premarket approval, similar to asking a regulator for permission to alter a certified product before selling the new version. For investors, it matters because the supplement triggers a review that can affect how quickly a revised device reaches the market, add development or compliance costs, and change future sales or competitive positioning.

LungFit PH II medical

"approval by the FDA of the Company's pending premarket approval supplement for LungFit PH II"

conversion or exercise price financial

"conversion_or_exercise_price: 5.5100 for the warrants"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/31/2026 - 06:55 PM Accepted by SEC EDGAR 07/31/2026 - 06:55 PM Learn about SEC filing dates

FAQ

What did Beyond Air (XAIR) CEO Robert Scott Goodman buy on July 29, 2026?

Robert Scott Goodman bought 34,722 shares of Beyond Air common stock at $5.76 per share. In the same transaction, he also acquired 34,722 Series A Warrants and 34,722 Series B Warrants, each exercisable for common stock at $5.51 per share.

How many Beyond Air (XAIR) common shares does the CEO hold after this transaction?

After the reported purchase, Robert Scott Goodman directly holds 34,822 shares of Beyond Air common stock. This reflects his prior holdings plus the newly acquired 34,722 shares disclosed for July 29, 2026, all shown as directly owned.

What are the key terms of the Series A Warrants acquired by the XAIR CEO?

The acquired 34,722 Series A Warrants are exercisable immediately at a $5.51 per share exercise price. They expire on the earlier of (i) one year after issuance or (ii) 45 days following FDA approval of Beyond Air’s pending premarket approval supplement for LungFit PH II.

What are the key terms of the Series B Warrants acquired by the XAIR CEO?

The 34,722 Series B Warrants are exercisable immediately at a $5.51 per share exercise price. According to the disclosure, these Series B Warrants expire five years following the date of issuance, providing a longer exercise window than the Series A Warrants.

How were the Beyond Air (XAIR) stock and warrants priced in the CEO’s transaction?

Each share of common stock was purchased at $5.76 per share. A footnote states that each Series A Warrant and Series B Warrant was purchased together with one share of common stock for a combined purchase price of $5.76 for that stock-and-warrants bundle.

Were the XAIR CEO’s transactions marked as under a Rule 10b5-1 trading plan?

The disclosure’s Rule 10b5-1 checkbox is unchecked, and there is no footnote describing a Rule 10b5-1 trading plan in connection with these transactions. The available information does not characterize the purchases as being made under a pre-arranged plan.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Goodman Robert Scott

(Last) (First) (Middle)

C/O BEYOND AIR, INC.

900 STEWART AVENUE, SUITE 301

(Street)

GARDEN CITY NEW YORK 11530

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Beyond Air, Inc. [ XAIR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/29/2026		P		34,722	A	$5.76	34,822	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series A Warrants	$5.51	07/29/2026	07/29/2026	P		34,722		(1)	(2)	Common Stock	34,722	(3)	34,722	D
Series B Warrants	$5.51	07/29/2026	07/29/2026	P		34,722		(1)	(4)	Common Stock	34,722	(3)	34,722	D

Explanation of Responses:

1. Exercisable immediately upon issuance

2. Expiration on the earlier of (i) the first anniversary of their issuance or (ii) the date that is 45 days following approval by the FDA of the Company's pending premarket approval supplement for LungFit PH II

3. Each Series A Warrant and Series B Warrant was purchased together with one share of common stock for a combined purchase price of $5.76.

4. 5 years following date of issuance

	/s/ Robert Scott Goodman	07/31/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)